Terrence F. Blaschke, MD, is Professor of Medicine and of Molecular Pharmacology (Active Emeritus) at Stanford University School of Medicine, Adjunct Professor of Bioengineering and Therapeutic Sciences at UCSF and Adjunct Professor of Medicine at Indiana University. Dr. Blaschke received his medical degree from Columbia University College of Physicians and Surgeons, and after residency training in Internal Medicine at UCLA Center for Health Sciences, he was a Clinical Associate in the NCI/Metabolism Branch at the National Institutes of Health. Following fellowship training in Clinical Pharmacology at the University of California, San Francisco, Dr. Blaschke joined the faculty at the Stanford University School of Medicine in 1974. Dr. Blaschke’s research has been primarily in the area of clinical investigation, with considerable involvement related to the clinical pharmacology of drugs used in patients with HIV infection, and an emphasis on modeling exposure-response relationships. He was a member of the AIDS Clinical Trials Group at its inception, and has served as chair of the Pharmacology Committee and a member of the Executive Committee of the ACTG. His current efforts in HIV are directed at questions related to the use of antiretroviral agents in less developed countries. His interest in exposure-response has led to a related interest in the topic of patient adherence with prescribed treatment regimens in HIV-infected patients. His involvement in clinical trials and with the pharmaceutical industry has also lead to a strong interest in approaches to improve the drug development process Dr. Blaschke is a past president of the American Society for Clinical Pharmacology and Therapeutics. In 2002 he received the Rawls-Palmer award from ASCPT for significant contributions to drug investigation that bring the efforts of modern drug research to the care of patients, in 2006 received the Henry W. Elliott distinguished service award and in 2007 he received the Oscar B. Hunter Award, the highest award of the Society. He has been a consultant and past Chair of the Generic Drugs Advisory Committee of the US FDA and a member of the Nonprescription Drugs Advisory Committee. He chaired the Drug Utilization Review Panel of USP from 1995-2000.